The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Japanese 2011 guidelines for prevention and treatment of osteoporosis—executive summary
Open accessAbstract
INTRODUCTION: In 1998, the first Japanese practice guidelines on osteoporosis was published. It has been updated several times, with the most recent being the full-scale 2011 edition and its abridged edition. The present guidelines provide information for the managements of primary osteoporosis in postmenopausal women and men over 50 years old, a summary of the evidence for the treatment of secondary osteoporosis, and a summary of the evidence for the prevention of osteoporosis in younger people. METHOD: The present Executive Summary is primarily based on the content of the 2011 Japanese abridged edition. One of the key changes is revision of the criteria for initiation of pharmacological treatment, along with an introduction of the fracture risk factors used in FRAX®. Key figures and tables were selected from the Japanese abridged edition and a reference list was added. RESULT AND CONCLUSIONS: The essential points of the Japanese practice guidelines on osteoporosis were translated into English for the first time. It is hoped that the content of the guidelines becomes known throughout the world.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Estimated prevalence of osteoporosis in Japan. Osteoporosis was diagnosed from BMD at vertebrae L2–4 (a) and proximal femur (b). Data from Yoshimura [1] (Copyright© 2009 Springer Science + Business Media BV)](https://figures.cochat.ai/paper-figures/95f343ac3462455ba4efccd7f63d0829/japanese-2011-guidelines-for-prevention-and-treatment-of-osteoporosisexecutive-figure-1.jpg)

![Fig. 3 Procedure for the diagnosis of osteoporosis. YAM young adult mean (20 to 44 years of age). Adapted from Orimo [4] (Copyright© 2001 Springer Science + Business Media BV)](https://figures.cochat.ai/paper-figures/59dabff8e57f4cde9ee8ae63374d46b4/japanese-2011-guidelines-for-prevention-and-treatment-of-osteoporosisexecutive-figure-3.jpg)

![Fig. 5 Measurement of bone metabolic markers in drug treatment of osteoporosis. #1: in patients taking bisphosphonates, measure after stopping drug for at least 6 months, and in patients taking other osteoporosis drugs, measure after stopping drug for at least 1 month. #2: measure one type each of a resorption marker and formation marker. #3: excluding eldecalcitol. #4: in patients expected to be on long-term bisphosphonate therapy, measure bone resorption markers and BAP or P1NP. Nishizawa [6] (Copyright© 2012 Springer Science + Business Media BV)](https://figures.cochat.ai/paper-figures/fa943a5221d9428caa959157528f111c/japanese-2011-guidelines-for-prevention-and-treatment-of-osteoporosisexecutive-figure-5.jpg)
![Fig. 6 Diagnostic criteria for primary osteoporosis (updated in 2000). Primary osteoporosis is diagnosed according to these criteria in the absence of diseases causing low bone mass or secondary osteoporosis. #1: fragility fracture is a nontraumatic bone fracture that is caused by slight external force to a bone with low BMD (BMD less then 80 % of YAM). Sites of fracture include the spine, proximal femur, and the distal end of the radius. #2: BMD usually refers to lumbar BMD. However, when the measurement is inappropriate for reasons such as spinal deformity, the proximal femur BMD should be used. When measurement at those sites is difficult, BMD of the radius, second metacarpal bone, or calcaneus will be used. Revision of additional T-scores is under consideration. Adapted from Orimo [4] (Copyright © 2001 Springer Science + Business Media BV)](https://figures.cochat.ai/paper-figures/e7ce68df226e450d841779a56a1703f0/japanese-2011-guidelines-for-prevention-and-treatment-of-osteoporosisexecutive-figure-6.jpg)
![Fig. 7 Criteria for osteoporosis screening. Risk factors for osteoporosis: non-modifiable factors: aging, sex (female), race, family history, late menarche, early menopause, and history of fracture. Modifiable factors: deficiency of calcium, vitamin D, and K; excess intake of phosphorus and salt; excessive calorie restriction; low BMI; lack of physical activity and sunlight; smoking; and excess intake of alcohol and coffee Orimo [8]](https://figures.cochat.ai/paper-figures/d95e75d2061a4237bb48e2c18da2d5c7/japanese-2011-guidelines-for-prevention-and-treatment-of-osteoporosisexecutive-figure-7.jpg)

![Fig. 9 Meta-analyses on the efficacy of vitamin D. a Relative risk for vertebral fractures after treatment with vitamin D. RR relative risk, CI confidence interval. Open rhombus indicates using calcitriol and closed rhombus using alfacalcidol. Adapted from Papadimitropoulos [10] (Copyright© 2002 The Endocrine Society). b Compared risk of falling between vitamin D-treated group and control group. OR odds ratio, CI confidence interval. Adapted from Bischoff-Ferrari [11] (Copyright© 2004 American Medical Association)](https://figures.cochat.ai/paper-figures/8f7c14c549bb49fb894375f848245670/japanese-2011-guidelines-for-prevention-and-treatment-of-osteoporosisexecutive-figure-9.jpg)
![Fig. 10 Effect of eldecalcitol compared with alfacalcidol. a Change in lumbar BMD. Data are mean ± SE, *p < 0.001 vs alfacalcidol group by Student t test (Matsumoto [12] (Copyright© 2011 Elsevier)). b Incidence of vertebral fracture. Hazard ratio (HR) is 0.74 and 95 % confidence interval (CI) is 0.56–0.97. Data from Matsumoto [12] (Copyright© 2011 Elsevier). c Incidence of non-vertebral fractures. HR for three major non-vertebral fractures is 0.52 and 95 % CI is 0.29–0.93, p = 0.031. Three major non-vertebral sites mean humerus, wrist, and hip, i.e., the three sites of major non-vertebral fractures recognized as osteoporotic fractures in FRAX®. HR for wrist fractures is 0.29 and 95 % CI is 0.11–0.77, p = 0.005. Data from Matsumoto [12] (Copyright© 2011 Elsevier) and the website of Pharmaceuticals and Medical Devices Agency (in Japanese)](https://figures.cochat.ai/paper-figures/f160d444761249c7b26aeac8eeaab39c/japanese-2011-guidelines-for-prevention-and-treatment-of-osteoporosisexecutive-figure-10.jpg)
![Fig. 11 Meta-analysis on the efficacy of menatetrenone on fractures. OR odds ratio, CI confidence interval (Cockayne [13] (Copyright© 2006 American Medical Association))](https://figures.cochat.ai/paper-figures/2c54a6c71788469c8dab07b7d2906cdc/japanese-2011-guidelines-for-prevention-and-treatment-of-osteoporosisexecutive-figure-11.jpg)
![Fig. 12 Effect of minodronic acid on BMD and vertebral fracture. a Percent change in lumbar spine and total hip BMD. Solid line is minodronic acid 1 mg (n = 134) and broken line is alendronate 5 mg (n = 135). Data are mean ± SE (Hagino [14] (Copyright© 2009 Elsevier)). b Incidence of vertebral fracture. Solid line is minodronic acid (n = 339) and broken line is placebo (n = 328). Relative risk is 0.411 (95 % confidence interval 0.267–0.634) by Cox regression model. *p < 0.0001 by log-rank test between the groups (Matsumoto [15] (Copyright© 2009 Springer Science + Business Media BV))](https://figures.cochat.ai/paper-figures/1b4d916ff92b4d568f31734b154c88d5/japanese-2011-guidelines-for-prevention-and-treatment-of-osteoporosisexecutive-figure-12.jpg)
![Fig. 13 Effect of elcatonin on BMD and pain associated with vertebral fracture. a Percent change in lumbar spine BMD. Solid line is elcatonin (20 units per week) with 0.6 g calcium lactate and broken line is control (calcium lactate only). Data are mean ± SE. Numerals in parentheses denote number of patients. Comparison within groups: Student’s paired t-test, #p < 0.05; between groups: Student’s unpaired t-test, *p < 0.05. Orimo H [16] (Copyright© 1996 Springer Science + Business Media BV). b Percent change in pain associated with getting up evaluated with visual analog scale (VAS). Solid line is elcatonin (20 units per week, n = 44) and broken line is control (untreated, n = 42). Two-way repeated-measures ANOVA, *p < 0.05, **p < 0.01, NS not significant. Mann–Whitney U test, #p < 0.05, ##p < 0.01 (Nakano [17])](https://figures.cochat.ai/paper-figures/5e1f9eb7c4b849639d6491df289af00f/japanese-2011-guidelines-for-prevention-and-treatment-of-osteoporosisexecutive-figure-13.jpg)
![Fig. 14 Efficacy of combination therapy with alendronate and active vitamin D3 on vertebral fracture. HR hazard ratio of incident vertebral fracture, CI confidence interval (Orimo [18] (Copyright© 2011 Informa Plc.))](https://figures.cochat.ai/paper-figures/ac63802364e84926b706bf1ea1915176/japanese-2011-guidelines-for-prevention-and-treatment-of-osteoporosisexecutive-figure-14.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It was apparent that some systematic reviews and guidelines, particularly for the earlier three patient groups, would be different for vitamin K and risedronate 2.5 mg/day if the affected trial reports were removed”
From An investigation into the impact and implications of published papers from retracted research: systematic search of affected literature (2019) · cites this paper as [23]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and that some affected systematic reviews and guidelines have themselves been widely disseminated.18 23 30 49 52”
From An investigation into the impact and implications of published papers from retracted research: systematic search of affected literature (2019) · cites this paper as [23]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Importantly, this 2006 meta-analysis, without any caveat related to the sensitivity analysis, is the sole evidence cited for vitamin K preventing vertebral and non-vertebral fractures in the journal publication of the 2011 Japanese guidelines for osteoporosis23 (122 citations, October 2018).”
From An investigation into the impact and implications of published papers from retracted research: systematic search of affected literature (2019) · cites this paper as [23]
The cited source says what the claim attributes to it.
In the citing paper
“However, for randomised trials in clinical areas affecting systematic reviews and guidelines further propagation is likely, as we show in the case of the systematic review by Cockayne et al 18 and its influence on Japanese osteoporosis guidelines.23”
From An investigation into the impact and implications of published papers from retracted research: systematic search of affected literature (2019) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effect of Vitamin D on Falls: A Meta-analysis
Bischoff-Ferrari, H. A., Dawson-Hughes, B., Willett, W. C., Staehelin, H. B., Bazemore, M. G., Zee, R. Y., & Wong, J. B. (2004) · JAMA · doi:10.1001/jama.291.16.1999 · Cited by 1,324
Yoshimura, N., Muraki, S., Oka, H., Mabuchi, A., En-Yo, Y., Yoshida, M., Saika, A., Yoshida, H., Suzuki, T., Yamamoto, S., et al. (2009) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-009-0080-8 · Cited by 819
Self-citationMacLean, C., Newberry, S., Maglione, M., McMahon, M., Ranganath, V., Suttorp, M., Mojica, W., Timmer, M., Alexander, A., McNamara, M., et al. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-3-200802050-00198 · Cited by 529
Diagnostic criteria for primary osteoporosis: year 2000 revision
Orimo, H., Hayashi, Y., Fukunaga, M., Sone, T., Fujiwara, S., Shiraki, M., Kushida, K., Miyamoto, S., Soen, S., Nishimura, J., et al. (2001) · Journal of Bone and Mineral Metabolism · doi:10.1007/s007740170001 · Cited by 465
Self-citationCockayne, S., Adamson, J., Lanham-New, S., Shearer, M. J., Gilbody, S., & Torgerson, D. J. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.12.1256 · Cited by 361 · cited 1×
“OR odds ratio,CI confidence interval (Cockayne [13] (Copyright© 2006American Medical Association)) Arch Osteoporos”
BackgroundPapadimitropoulos, E., Wells, G., Shea, B., Gillespie, W., Weaver, B., Zytaruk, N., Cranney, A., Adachi, J., Tugwell, P., Josse, R., et al. (2002) · Endocrine Reviews · doi:10.1210/er.2001-8002 · Cited by 302
Matsumoto, T., Ito, M., Hayashi, Y., Hirota, T., Tanigawara, Y., Sone, T., Fukunaga, M., Shiraki, M., & Nakamura, T. (2011) · Bone · doi:10.1016/j.bone.2011.07.011 · Cited by 189
Self-citationNishizawà, Y., Ohta, H., Miura, M., Inaba, M., Ichimura, S., Shiraki, M., Takada, J., Chaki, O., Hagino, H., Fujiwara, S., et al. (2012) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-012-0392-y · Cited by 143
Self-citationHip fracture incidence in Japan: estimates of new patients in 2007 and 20-year trends
Orimo, H., Yaegashi, Y., Onoda, T., Fukushima, Y., Hosoi, T., & Sakata, K. (2009) · Archives of Osteoporosis · doi:10.1007/s11657-009-0031-y · Cited by 143
Self-citationMatsumoto, T., Hagino, H., Shiraki, M., Fukunaga, M., Nakano, T., Takaoka, K., Morii, H., Ohashi, Y., & Nakamura, T. (2008) · Osteoporosis International · doi:10.1007/s00198-008-0816-7 · Cited by 109
Self-citation
Research works printed but not linked: 3
- You K (2011) Osteoporos Jpn 19:626, in Japanese
- Orimo H, Hosoi T, Fukunaga M (eds) (2009) Manual for osteoporosis screening and health guidance. Life Science Publishing, Tokyo, in Japanese
- Nakano T (2011) Clinical effect of calcitonin (elcatonin) on acute pain for osteoporotic vertebral fracture: semi blind randomized controlled trial. Osteoporos Jpn 19:279
Cited by
The Advisory Board of the National Osteoporosis Guideline Group, Kanis, J. A., Harvey, N. C., Cooper, C., Johansson, H., Odén, A., & McCloskey, E. V. (2016) · Archives of Osteoporosis · doi:10.1007/s11657-016-0278-z · Cited by 421
“95 Hungary Hungarian Society for Osteoporosis and Osteoarthrology [82] 20 3 Japan Japan Osteoporosis Society; Japanese Society for Bone and Mineral Research; Japan Osteoporosis Foundation [31] 15 Japan Academia [83] 10 5 Lebanon Ministry of Public Health and multiple societies [84] 10 Malaysia Ministry of Health, Mala…”
BackgroundInfluentialAn overview of the use of the fracture risk assessment tool (FRAX) in osteoporosis
Schini, M., Johansson, H., Harvey, N. C., Lorentzon, M., Kanis, J. A., & McCloskey, E. V. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02219-9 · Cited by 194
“In other cases, for example China and Japan, thresholds have been adapted to (usually lower) mean fracture incidence in the population [37, 38].”
BackgroundLi, K., Wang, X.-F., Li, D.-Y., Chen, Y.-C., Zhao, L.-J., Liu, X.-G., Guo, Y.-F., Shen, J., Lin, X., Deng, J., et al. (2018) · Clinical Interventions in Aging · doi:10.2147/cia.s157523 · Cited by 191
Yasaka, K., Akai, H., Kunimatsu, A., Kiryu, S., & Abe, O. (2020) · European Radiology · doi:10.1007/s00330-020-06677-0 · Cited by 157
A decade of FRAX: how has it changed the management of osteoporosis?
Kanis, J. А., Harvey, N. C., Johansson, H., Liu, E., Vandenput, L., Lorentzon, M., Leslie, W. D., & McCloskey, E. V. (2020) · Aging Clinical and Experimental Research · doi:10.1007/s40520-019-01432-y · Cited by 165
Metadata
- Authors
- Orimo, H., Nakamura, T., Hosoi, T., Iki, M., Uenishi, K., Endo, N., Ohta, H., Shiraki, M., Sugimoto, T., Suzuki, T., Soen, S., Nishizawa, Y., Hagino, H., Fukunaga, M., & Fujiwara, S.
- Affiliations
- Japan Osteoporosis Foundation (JP)
- University of Occupational and Environmental Health Japan (JP)
- National Center for Geriatrics and Gerontology (JP)
- Kindai University (JP)
- Japan Nutrition University (JP)
- Niigata University (JP)
- Sanno Medical Center (JP)
- Research Institute and Practice for Involutional Diseases (JP)
- Shimane University (JP)
- Research Institute, National Center for Geriatrics and Gerontology (JP)
- Tottori University (JP)
- Kawasaki Medical School (JP)
- Radiation Effects Research Foundation (JP)
- Corresponding author
- Hosoi, Takayuki
- ORCID
- Venue
- Archives of Osteoporosis
- Published
- 2012-12
- Volume
- 7
- Issue
- 1-2
- Pages
- 3-20
- ISSN
- 1862-3514 (ISSN-L)
- 1862-3522
- PMC
- PMC3517709
- OpenAlex
- W2030203316
- Cited by
- 358
- References
- 15
- Citations by year
- 2026: 12 · 2025: 19 · 2024: 27 · 2023: 22 · 2022: 27 · 2021: 35 · 2020: 34 · 2019: 28 · 2018: 32 · 2017: 33 · 2016: 38 · 2015: 22 · 2014: 14 · 2013: 13 · 2012: 2
- FWCI
- 17.43
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- Archives of Osteoporosis (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- osteoporosis, osteoporosis prevention, osteoporosis treatment, postmenopausal women, men over 50, secondary osteoporosis, fracture risk assessment, FRAX, Japanese clinical practice guidelines
- MeSH terms
- Adult, Aged, Aged, 80 and over, Female, Humans, Japan, Male, Middle Aged, Osteoporosis, Risk Factors, Incidence, Practice Guidelines as Topic, Age Distribution, Sex Distribution, Antirheumatic Agents, Fractures, Bone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Japanese 2011 guidelines for prevention and treatment of osteoporosis—executive summary. https://app.cochat.ai/papers/10.1007/s11657-012-0109-9
- The paper
- Orimo, H., Nakamura, T., Hosoi, T., Iki, M., Uenishi, K., Endo, N., Ohta, H., Shiraki, M., Sugimoto, T., Suzuki, T., Soen, S., Nishizawa, Y., Hagino, H., Fukunaga, M., & Fujiwara, S. (2012). Japanese 2011 guidelines for prevention and treatment of osteoporosis—executive summary. Archives of Osteoporosis. https://doi.org/10.1007/s11657-012-0109-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.